Technology authored by dr. Marek Markiewicz and implemented at PERFECT DENTAL CLINIC refers to an innovative way of obtaining a unique augmentation material for bone augmentation within the oral cavity thanks to our original procedure. So far usage of this ingredients in augmentation, according to the assumption of this innovative solution, has not been utilized in implantology, and thus, it is a novelty on a national scale.
A perfected service, including osseous tissue restoration, will be conducted on the basis of our original augmentation material, which will shorten the 9-12-month period of augmentation material healing (characteristic for using only xenogeneic/allogeneic biomaterial) and osseous tissue regeneration to 3 months. Moreover, this is an alternative for an autogenous graft, whose healing period equals about 3-4 months, whereby, it is not burdened with analogous risk of osseous tissue loss after the healing period; with autogenous grafts, considerable resorptions of autogenous graft material up to 50% are often observed.
It is important from the perspective of its further usage in bone augmentation procedure within the facial skeleton, as it is a process that precedes placement of dental implants.
Currently at most clinics, the main method used in implantology for augmenting amount of bone needed for placing an implant is utilizing an autogenous bone or pure xenogeneic/synthetic material (the method is chosen with regard to osseous tissue deficits). Present implantology methods do not provide for using our original procedure as the basic ingredient of augmentation material for restoring bone. Having performed a literature review, it was revealed that similar techniques in osseous tissue regeneration processes appear in orthopaedics, however, they have not been used in dentistry yet. In the light of the above, innovative technology is a real breakthrough in bone augmentation in implantology by means of our original recipe for augmentation material.
Augmentation material, i.e. the one that restores bones and created according to the assumptions of the new original technology, will be used to restore osseous tissue in various areas of the facial skeleton, including areas with poor blood supply such as the mandible, where using a standard xenogeneic or autogenic material is very problematic and due to limited penetration of solid mandibular osseous tissue by cells from myeloid spaces there appear complications and osseous tissue is irregular, poorly supplied with blood, has poor quality and tendency towards resorption. Using our original method will send a number of cell signals at the collection site supporting osteogenic and osteoinductive processes.
Thanks to that, a new bone will be characterized by better histological parameters, lower tendency towards resorption, and in terms of quality it will constitute a much better bone bed for a dental implant that is placed during the subsequent stage.
New original recipe for augmentation material guarantee obtaining required features of the augmentation material, i.e. osteoconduction, osteoinduction, and osteogenesis – all necessary considering the purpose of the preparation.
According to the assumptions of the implemented recipe, advantages of optimally compounded augmentation material shall include:
- Shortened period of early healing;
- Lower risk of sutures coming apart, and early post-surgical complications;
- Shortened total regeneration time down to 3 months (right after this period it will be possible to place an implant);
- No resorption as compared with using autogenous materials only;
- No need to collect autogenous blocks/chips and additionally traumatize the patient.
Volume of particular ingredients of augmentation material depends on volume of osseous tissue loss at patient’s collection site. The deficit is precisely evaluated at treatment planning stage by an implantologist and his/her team on the basis of radiologic measurements and cone beam CT.
Proportion of the augmentation material and its recipe are formed on the basis of our experiences as well as clinical trials in orthopaedics and maxillofacial surgery.